Cargando…

Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study

INTRODUCTION: Both dipeptidyl peptidase-4 inhibitors and α-glucosidase inhibitors (α-GI) have been reported to change the incretin and insulin secretion. To examine the effects of acarbose, miglitol, and sitagliptin on glucose metabolism and secretion of gut peptides, we conducted a crossover study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueno, Hiroaki, Tsuchimochi, Wakaba, Wang, Hong-Wei, Yamashita, Eiichiro, Tsubouchi, Chikako, Nagamine, Kazuhiro, Sakoda, Hideyuki, Nakazato, Masamitsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478179/ https://www.ncbi.nlm.nih.gov/pubmed/26055217 http://dx.doi.org/10.1007/s13300-015-0113-3

Ejemplares similares

Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes
por: Kishimoto, Miyako, et al.
Publicado: (2012)

Kinetic Determination of Acarbose and Miglitol in Bulk and Pharmaceutical Formulations Using Alkaline Potassium Permanganate
por: Ibrahim, F. A., et al.
Publicado: (2007)

Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study
por: Ueno, Hiroaki, et al.
Publicado: (2018)

Concurrent Use of Teneligliptin and Canagliflozin Improves Glycemic Control with Beneficial Effects on Plasma Glucagon and Glucagon-Like Peptide-1: A Single-Arm Study
por: Noda, Tomoho, et al.
Publicado: (2019)

Functional interaction between Ghrelin and GLP-1 regulates feeding through the vagal afferent system
por: Zhang, Weidong, et al.
Publicado: (2020)

Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients
por: Kubo, Sayaka, et al.
Publicado: (2010)

Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats
por: Zhang, Minchun, et al.
Publicado: (2019)

A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers
por: Kishimoto, Miyako, et al.
Publicado: (2011)

Additive Effects of Miglitol and Anagliptin on Insulin-Treated Type 2 Diabetes Mellitus: A Case Study
por: Kishimoto, Miyako, et al.
Publicado: (2014)

Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
por: Yang, Hae Kyung, et al.
Publicado: (2019)

Current status of diabetes treatment in Miyazaki Prefecture, Japan: Results of a questionnaire survey conducted in 2016 and 2020
por: Uehira, Yudai, et al.
Publicado: (2022)

Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus
por: Nomura, Shosaku, et al.
Publicado: (2011)

Impaired adaptation of energy intake induces severe obesity in aged mice on a high‐fat diet
por: Okada, Tadashi, et al.
Publicado: (2019)

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas
por: Hsieh, Sheng-Hwu, et al.
Publicado: (2010)

Is ghrelin a glucagon‐like peptide‐1 secretagogue?
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Mechanistic relationship between the vagal afferent pathway, central nervous system and peripheral organs in appetite regulation
por: Ueno, Hiroaki, et al.
Publicado: (2016)

Neuromedin U uses Gα(i2) and Gα(o) to suppress glucose-stimulated Ca(2+) signaling and insulin secretion in pancreatic β cells
por: Zhang, Weidong, et al.
Publicado: (2021)

Effects of the addition of acarbose to insulin and non-insulin regimens in veterans with type 2 diabetes mellitus
por: Wettergreen, Sara A., et al.
Publicado: (2016)

Stability-Indicating RP-HPLC Method for Estimation of Miglitol in Bulk and Tablets
por: Shrivastava, B., et al.
Publicado: (2010)

Review: Miglitol has potential as a therapeutic drug against obesity
por: Sugimoto, Satoru, et al.
Publicado: (2015)

Acarbose is again on the stage
por: Altay, Mustafa
Publicado: (2022)

Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, Double-blind, Controlled Crossover Trial
por: Zhang, Xiuying, et al.
Publicado: (2017)

Comparative Analysis of Clinical Effects of Insulin Aspart Combined with Acarbose and Metformin in the Treatment of Diabetes Mellitus
por: Jin, Hongmei, et al.
Publicado: (2022)

Incretin Kinetics Before and After Miglitol in Japanese Patients With Late Dumping Syndrome
por: Amagai, Mari, et al.
Publicado: (2017)

Acarbose treatments improve arterial stiffness in patients with type 2 diabetes mellitus
por: Uzui, Hiroyasu, et al.
Publicado: (2011)

Comparison of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus
por: Ziaee, Amir, et al.
Publicado: (2017)

Retracted: Comparative Analysis of Clinical Effects of Insulin Aspart Combined with Acarbose and Metformin in the Treatment of Diabetes Mellitus
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Restoration of metabolic inflammation-related ghrelin resistance by weight loss
por: Naznin, Farhana, et al.
Publicado: (2017)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
por: Kim, Ji Hyun
Publicado: (2015)

Exploration of suitable pharmacodynamic parameters for acarbose bioequivalence evaluation: A series of clinical trials with branded acarbose
por: Huang, Jie, et al.
Publicado: (2020)

Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus
por: Wu, Honghua, et al.
Publicado: (2017)

Development and Validation of Miglitol and Its Impurities by RP-HPLC and Characterization Using Mass Spectrometry Techniques
por: Balakumaran, Kesavan, et al.
Publicado: (2016)

Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model
por: Kishida, Yumi, et al.
Publicado: (2017)

On the potential of acarbose to reduce cardiovascular disease
por: Standl, Eberhard, et al.
Publicado: (2014)

Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study
por: Sato, Masahiro, et al.
Publicado: (2023)

Predictors of acarbose therapeutic efficacy in newly diagnosed type 2 diabetes mellitus patients in China
por: Zhang, Rong, et al.
Publicado: (2022)

Liver-expressed antimicrobial peptide 2 antagonizes the effect of ghrelin in rodents
por: Islam, Md Nurul, et al.
Publicado: (2019)

Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia
por: Kitano, Daisuke, et al.
Publicado: (2013)

Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion
por: Lee, Eun Young, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hfjka4tif3t3sgh2ghciga3ogm